Ekso Bionics Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ekso Bionics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Ekso Bionics stock.
View analyst ratings for Ekso Bionics or view top-rated stocks.

Wall Street analysts have given Ekso Bionics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Ekso Bionics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Ekso Bionics saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 247,000 shares, an increase of 31.4% from the December 31st total of 188,000 shares. Based on an average daily trading volume, of 168,900 shares, the short-interest ratio is presently 1.5 days. Approximately 3.3% of the company's shares are short sold.
View Ekso Bionics' Short Interest.

Ekso Bionics is scheduled to release its next quarterly earnings announcement on Thursday, April 29th 2021.
View our earnings forecast for Ekso Bionics.

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) issued its quarterly earnings results on Thursday, February, 25th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.30) by $0.18. Ekso Bionics had a negative trailing twelve-month return on equity of 201.69% and a negative net margin of 140.82%.
View Ekso Bionics' earnings history.

Ekso Bionics' stock was trading at $0.2616 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, EKSO shares have increased by 2,633.2% and is now trading at $7.15.
View which stocks have been most impacted by COVID-19.

Shares of Ekso Bionics reverse split on the morning of Thursday, May 5th 2016. The 1-7 reverse split was announced on Wednesday, May 4th 2016. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 4th 2016. An investor that had 100 shares of Ekso Bionics stock prior to the reverse split would have 14 shares after the split.

Ekso Bionics updated its fourth quarter 2020 After-Hours earnings guidance on Wednesday, January, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.3-2.3 million, compared to the consensus revenue estimate of $2.58 million.

3 brokerages have issued twelve-month target prices for Ekso Bionics' shares. Their forecasts range from $8.00 to $11.00. On average, they anticipate Ekso Bionics' share price to reach $9.33 in the next twelve months. This suggests a possible upside of 30.5% from the stock's current price.
View analysts' price targets for Ekso Bionics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Ekso Bionics include Taylor Devices (TAYD), International Baler (IBAL), Integrated Environmental Technologies (IEVM), China Energy Recovery (CGYV), Reelcause (RCIT) and RINO International (RINO).
View all of EKSO's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ekso Bionics investors own include OrganiGram (OGI), Gran Tierra Energy (GTE), KushCo (KSHB), Cannabics Pharmaceuticals (CNBX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), Novan (NOVN), Pennsylvania Real Estate Investment Trust (PEI) and ADMA Biologics (ADMA).

Ekso Bionics trades on the NASDAQ under the ticker symbol "EKSO."

Ekso Bionics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (0.09%).
View institutional ownership trends for Ekso Bionics.

EKSO stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC.
View insider buying and selling activity for Ekso Bionics or or view top insider-buying stocks.

Shares of EKSO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EKSO stock can currently be purchased for approximately $7.15.

Ekso Bionics has a market capitalization of $87.37 million and generates $13.92 million in revenue each year. The company earns $-12,130,000.00 in net income (profit) each year or ($3.45) on an earnings per share basis.

Ekso Bionics employs 67 workers across the globe.

The official website for Ekso Bionics is www.eksobionics.com.

Ekso Bionics is headquartered at 1414 HARBOUR WAY SOUTH SUITE 1201, RICHMOND CA, 94804.

Ekso Bionics' mailing address is 1414 HARBOUR WAY SOUTH SUITE 1201, RICHMOND CA, 94804. The company can be reached via phone at 510-984-1761 or via email at [email protected]